跳转至内容
Merck
CN
  • Glutaredoxin-1 Deficiency Causes Fatty Liver and Dyslipidemia by Inhibiting Sirtuin-1.

Glutaredoxin-1 Deficiency Causes Fatty Liver and Dyslipidemia by Inhibiting Sirtuin-1.

Antioxidants & redox signaling (2016-12-14)
Di Shao, Jingyan Han, Xiuyun Hou, Jessica Fry, Jessica B Behring, Francesca Seta, Michelle T Long, Hemant K Roy, Richard A Cohen, Reiko Matsui, Markus M Bachschmid
摘要

Nonalcoholic fatty liver (NAFL) is a common liver disease associated with metabolic syndrome, obesity, and diabetes that is rising in prevalence worldwide. Various molecular perturbations of key regulators and enzymes in hepatic lipid metabolism cause NAFL. However, redox regulation through glutathione (GSH) adducts in NAFL remains largely elusive. Glutaredoxin-1 (Glrx) is a small thioltransferase that removes protein GSH adducts without having direct antioxidant properties. The liver contains abundant Glrx but its metabolic function is unknown. Here we report that normal diet-fed Glrx-deficient mice (Glrx These data suggest an essential role of hepatic Glrx in regulating SirT1, which controls protein glutathione adducts in the pathogenesis of hepatic steatosis. We provide a novel redox-dependent mechanism for regulation of hepatic lipid metabolism, and propose that upregulation of hepatic Glrx may be a beneficial strategy for NAFL. Antioxid. Redox Signal. 27, 313-327.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
DL-半胱氨酸, technical grade